Arcus Biosciences, Inc. (RCUS) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $28.12 (-0.50%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 12, 2026 | Richard Law | Goldman Sachs | $28.00 | -0.4% |
| Oct 30, 2025 | Salveen Richter | Goldman Sachs | $16.00 | -43.1% |
| Oct 7, 2025 | Asthika Goonewardene | Truist Financial | $39.00 | +38.7% |
| May 7, 2025 | Eva Fortea Verdejo | Wells Fargo | $26.00 | -7.5% |
| Oct 24, 2024 | Yigal Nochomovitz | Citigroup | $46.00 | +63.6% |
| Oct 21, 2024 | Emily Bodnar | H.C. Wainwright | $20.00 | -28.9% |
| Oct 8, 2024 | Eva Fortea Verdejo | Wells Fargo | $29.00 | +3.1% |
| Oct 8, 2024 | Judah Frommer | Morgan Stanley | $35.00 | +24.5% |
| Aug 9, 2024 | Jason Zemansky | Bank of America Securities | $23.00 | -18.2% |
| Jul 8, 2024 | Peter Lawson | Barclays | $25.00 | -11.1% |
| Jun 24, 2024 | Asthika Goonewardene | Truist Financial | $44.00 | +56.5% |
| Jun 4, 2024 | Peter Lawson | Barclays | $35.00 | +24.5% |
| May 11, 2022 | Robert Driscoll | Wedbush | $42.00 | +49.4% |
Top Analysts Covering RCUS
RCUS vs Sector & Market
| Metric | RCUS | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.25 | 2.25 | 2.42 |
| Analyst Count | 8 | 8 | 19 |
| Target Upside | +20.3% | +16366.1% | +18.0% |
| P/E Ratio | -7.55 | 3.02 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $52M | $91M | $231M | 9 |
| 2027-12-31 | $22M | $110M | $200M | 9 |
| 2028-03-31 | $97M | $104M | $118M | 2 |
| 2028-06-30 | $136M | $147M | $166M | 2 |
| 2028-09-30 | $55M | $59M | $67M | 2 |
| 2028-12-31 | $95M | $103M | $116M | 2 |
| 2029-03-31 | $109M | $118M | $133M | 5 |
| 2029-06-30 | $129M | $139M | $157M | 4 |
| 2029-09-30 | $151M | $163M | $184M | 4 |
| 2029-12-31 | $173M | $187M | $211M | 5 |
| 2030-12-31 | $257M | $948M | $2.09B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-5.35 | $-3.83 | $-2.32 | 7 |
| 2027-12-31 | $-4.35 | $-3.33 | $-2.08 | 6 |
| 2028-03-31 | $-1.11 | $-0.95 | $-0.86 | 1 |
| 2028-06-30 | $-1.10 | $-0.94 | $-0.85 | 1 |
| 2028-09-30 | $-0.84 | $-0.72 | $-0.65 | 1 |
| 2028-12-31 | $-0.65 | $-0.56 | $-0.50 | 1 |
| 2029-03-31 | $-0.59 | $-0.51 | $-0.46 | 1 |
| 2029-06-30 | $-0.51 | $-0.43 | $-0.39 | 1 |
| 2029-09-30 | $-0.42 | $-0.36 | $-0.32 | 1 |
| 2029-12-31 | $-0.30 | $-0.26 | $-0.23 | 1 |
| 2030-12-31 | $0.09 | $1.74 | $4.46 | 6 |
Frequently Asked Questions
What is the analyst consensus for RCUS?
The consensus among 8 analysts covering Arcus Biosciences, Inc. (RCUS) is Buy with an average price target of $31.75.
What is the highest price target for RCUS?
The highest price target for RCUS is $46.00, set by Yigal Nochomovitz at Citigroup on 2024-10-24.
What is the lowest price target for RCUS?
The lowest price target for RCUS is $16.00, set by Salveen Richter at Goldman Sachs on 2025-10-30.
How many analysts cover RCUS?
8 analysts have issued ratings for Arcus Biosciences, Inc. in the past 12 months.
Is RCUS a buy or sell right now?
Based on 8 analyst ratings, RCUS has a consensus rating of Buy (2.25/5) with a +20.3% upside to the consensus target of $31.75.
What are the earnings estimates for RCUS?
Analysts estimate RCUS will report EPS of $-3.83 for the period ending 2026-12-31, with revenue estimated at $91M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.